Medtronic conducted a post market clinical follow-up (pmcf) survey to seek out potential new risks and assess performance of the resolute integrity rx coronary drug-eluting stent.Survey results from an interventional cardiologist in practice 12 years.In the past 12 months, the physician has used the resolute integrity stent 35 times.5 of the smallest (2.25 x 8 mm), 25 intermediate (2.25 x 12 mm to 4.00 x 34 mm) and 5 of the largest (4.00 x 38 mm) sizes of these stents were used.The following complications adverse events/effects were encountered in the using the resolute integrity product over the last 12 months: 3 coronary artery spasm events which were directly related to the device itself.It was stated that the coronary artery spasm events were associated specifically with the use of the device due to the coronary vessel diameter being overestimated.One of the 3 coronary artery spasm events required medical or surgical intervention.2 coronary artery dissection events which were directly related to the device itself.It was stated that the coronary artery dissection events were associated specifically with the use of the device due to the presence of massive calcification within the coronary artery.Both coronary artery dissection events required medical or surgical intervention.It was noted that none of the events above that were directly related to the device itself had previously been reported to medtronic.
|